← Back to Search

PARP Inhibitor

Pamiparib for Solid Tumors

Phase 1 & 2
Waitlist Available
Research Sponsored by BeiGene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose bgb-290 and tmz until date of death, assessed up to 5 years
Awards & highlights

Study Summary

This trial is testing a new combination cancer drug to see if it is safe and effective.

Eligible Conditions
  • Metastatic or Locally Advanced Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose bgb-290 and tmz until date of death, assessed up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose bgb-290 and tmz until date of death, assessed up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.
Number of participants experiencing Adverse Events (AEs)
Number of participants experiencing Severe Adverse Events (SAEs)
+1 more
Secondary outcome measures
Disease control rate (DCR)
Duration of response (DOR).
Overall survival (OS)
+4 more

Side effects data

From 2021 Phase 1 & 2 trial • 116 Patients • NCT03150862
73%
Nausea
73%
Fatigue
45%
Headache
35%
Constipation
35%
Decreased appetite
35%
Alopecia
33%
Anaemia
33%
Vomiting
30%
Diarrhoea
28%
Dizziness
25%
Dysgeusia
23%
Weight decreased
20%
Hemiparesis
18%
Platelet count decreased
15%
Aphasia
15%
Urinary incontinence
15%
Seizure
15%
Anxiety
15%
Insomnia
15%
Neutrophil count decreased
15%
White blood cell count decreased
15%
Memory impairment
13%
Fall
13%
Abdominal pain
10%
Dry mouth
10%
Cough
10%
Agitation
10%
Blood creatinine increased
10%
Hyponatraemia
10%
Oedema peripheral
10%
Thrombocytopenia
10%
Confusional state
8%
Tinnitus
8%
Nasal congestion
8%
Vision blurred
8%
Aspartate aminotransferase increased
8%
Alanine aminotransferase increased
8%
Lymphocyte count decreased
8%
Pulmonary embolism
8%
Malaise
8%
Hypophosphataemia
8%
Back pain
8%
Visual field defect
5%
Lymphopenia
5%
Skin atrophy
5%
Ear pain
5%
Hypoacusis
5%
Flatulence
5%
Cognitive disorder
5%
Hypoaesthesia
5%
Haematuria
5%
Neutropenia
5%
Abdominal distension
5%
Dyspepsia
5%
Asthenia
5%
Gait disturbance
5%
Otitis media
5%
Upper respiratory tract infection
5%
Contusion
5%
Radiation skin injury
5%
Hyperglycaemia
5%
Hypokalaemia
5%
Partial seizures
5%
Irritability
5%
Dermatitis acneiform
5%
Stomatitis
3%
Hydrocephalus
3%
Hypertension
3%
Cerebral cyst
3%
Suicide attempt
3%
Chest pain
3%
Dehydration
3%
Sinus congestion
3%
Dyspnoea
3%
Eructation
3%
Nephrolithiasis
3%
Hiccups
3%
Pyrexia
3%
Hemiplegia
3%
Bronchitis
3%
Wound infection
3%
Brain oedema
3%
Dysarthria
3%
Nervous system disorder
3%
Ear discomfort
3%
Mental status changes
3%
Dry eye
3%
Oral candidiasis
3%
Oral herpes
3%
Non-cardiac chest pain
3%
Radiation injury
3%
Blood bilirubin increased
3%
Night sweats
3%
Muscle spasms
3%
Disturbance in attention
3%
Depression
3%
Postoperative wound infection
3%
Sepsis
3%
Apraxia
3%
Psychogenic seizure
3%
Vasogenic cerebral oedema
3%
Dysphagia
3%
Sinusitis
3%
Urinary tract infection
3%
Hypernatraemia
3%
Hypoalbuminaemia
3%
Arthralgia
3%
Groin pain
3%
Muscular weakness
3%
Myalgia
3%
Pain in extremity
3%
Hypersomnia
3%
Paraesthesia
3%
Tremor
3%
Pollakiuria
3%
Rhinitis allergic
3%
Dermatitis
3%
Dermatitis contact
3%
Pruritus
3%
Rash maculo-papular
3%
Deep vein thrombosis
3%
Neck pain
3%
Syncope
3%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + Temozolomide
Arm C: E- Pamiparib + Temozolomide 60 mg
Arm A: DE-Pamiparib 4 Wks + RT 6 Wks
Arm A: DE- Pamiparib 6Wks + RT 6 Wks
Arm C: DE - Pamiparib + Temozolomide 20 mg
Arm C: DE - Pamiparib + Temozolomide 40 mg
Arm 1Arm A: DE - Pamiparib 2 Wks + Radiation Therapy (RT) 6 Wks

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose Expansion, 6 cohortsExperimental Treatment2 Interventions
Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles
Group II: Arm B (Dose Escalation) TMZ Continuous DosingExperimental Treatment2 Interventions
Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.
Group III: Arm A (Dose Escalation) TMZ Pulse DosingExperimental Treatment2 Interventions
Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Temozolomide
2010
Completed Phase 3
~1930
Pamiparib
2017
Completed Phase 2
~750

Find a Location

Who is running the clinical trial?

Myriad Genetics, Inc.Industry Sponsor
16 Previous Clinical Trials
5,250 Total Patients Enrolled
BeiGeneLead Sponsor
175 Previous Clinical Trials
28,675 Total Patients Enrolled
Maggie ZhangStudy DirectorBeiGene

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of individual is best suited for participating in this trial?

"Potential candidates must have metastatic or locally advanced solid tumours and be between the ages 18 to 99. At this time, 139 participants are needed for this medical trial."

Answered by AI

What conditions are commonly treated with Pamiparib?

"Pamiparib has a number of medical applications, such as treating nitrosourea treatment and advanced directives. It is also used to manage refractory mycosis fungoides and neuroblastoma."

Answered by AI

Is recruitment currently underway for this experiment?

"This trial is no longer open for patient enrollment. It was initially posted on June 28th 2017 and modified most recently in April of 2022. If you seek alternative clinical trials, 2387 studies that focus on metastatic or locally advanced solid tumors are actively recruiting participants while 212 investigations involving Pamiparib require additional enrollees."

Answered by AI

Can you provide a list of experiments conducted with Pamiparib?

"Pamiparib was initially studied in 2002 by Memorial Sloan Kettering Cancer Center, and since then the drug has been tested across 302 clinical trials. Currently, 212 live studies are underway with a sizable portion of them based around Houston, Texas."

Answered by AI

Is this an original research initiative?

"Since 2002, the development of Pamiparib has been ongoing. It was first trialled by Schering-Plough in that year and approved for Phase 2 drug status after 60 participants were tested. Currently, 212 live studies are being conducted across 986 cities in 40 countries around the world."

Answered by AI

Is the eligibility criteria for this trial limited to adults eighteen years or older?

"This medical trial is seeking individuals over 18 years old, but not yet a centenarian."

Answered by AI

How many health care centers are currently conducting this trial?

"Currently, 5 clinical trial sites are welcoming patients to participate. These locations include Houston, Dallas and Nashville as well as two other cities that may be more convenient for the patient in terms of travel time."

Answered by AI

What is the maximum patient capacity for this medical study?

"At present, this clinical trial is not seeking any additional patients. Having originally been posted on June 28th 2017 and last updated April 14th 2022, it does not appear to be recruiting presently. If you are searching for trials involving metastatic or locally advanced solid tumors there are 2387 studies open and 212 that involve Pamiparib currently enrolling participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
2017. "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03150810.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top